Is KMS Medisurgi overvalued or undervalued?

As of 27 June 2025, KMS Medisurgi's valuation grade has moved from risky to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 41.91, an EV to EBIT of 42.03, and an EV to Sales ratio of 3.02. These ratios suggest that the stock is trading at a premium compared to its earnings and sales, which raises concerns about its sustainability at these levels. In comparison to its peers, KMS Medisurgi's valuation metrics are notably high. For instance, Poly Medicure has a PE ratio of 64.67 and an EV to EBITDA of 46.03, while Vimta Labs, which is considered fairly valued, has a PE ratio of 31.91. The stark difference in valuation highlights that KMS Medisurgi is not only overvalued relative to its industry but also compared to companies with better growth prospects. Additionally, while KMS Medisurgi has seen impressive returns over the past three years, outperforming the Sensex significantly, its current valuation does not seem justified given the high ratios and the competitive landscape.